Treatment of anaplastic glioma - PubMed
Review
Treatment of anaplastic glioma
Wolfgang Wick et al. Cancer Treat Res. 2015.
Abstract
Anaplastic gliomas have received increasing attention over the past years. As opposed to glioblastoma, where the focus has been on the evaluation of novel compounds (with mainly disappointing results), in anaplastic gliomas relevant progress was generated with genotoxic therapies and translational work on biomarkers. Anaplastic gliomas are classified using single biomarkers, namely isocitrate dehydrogenase (IDH) or the related CpG island methylator phenotype (CIMP), alpha-thalassemia/mental retardation syndrome X-linked (ATRX), telomerase reverse transcriptase (TERT), p53, 1p/19q, and O(6)-methylguanine DNA-methyltransferase (MGMT). With these molecular biomarkers, three main prognostically distinct groups have been defined: (i) CIMP-negative anaplastic gliomas, which have a similar prognosis as glioblastoma, (ii) CIMP-positive 1p/19q intact, and (iii) CIMP-positive 1p/19q codeleted gliomas. In the CIMP-negative, mainly IDH wild-type group, MGMT promoter methylation may be used to identify patients who benefit from alkylating chemotherapy. The mutually exclusive ATRX losses and 1p/19q codeletions are used to subcategorize anaplastic tumors with a mixed histology according to microscopic features. This eliminates the biological basis and clinical necessity for the diagnosis of mixed gliomas (anaplastic oligoastrocytomas). Retrospective long-term analysis of the EORTC 26951 and RTOG 9402 trials revealed that patients with tumors harboring 1p/19q codeletions benefit from addition of procarbazine, lomustine, and vincristine (PCV) chemotherapy to primary radiotherapy. RTOG 9402 suggests that this may be the case also for patients with 1p/19q intact tumors, but IDH mutation. Future developments in addition to the ongoing CATNON and CODEL trials, will focus on further refinement of the molecular predictors and development of treatments that not only increase survival but also maintain neurological function, cognition, and health-related quality of life.
Similar articles
-
Anaplastic glioma: current treatment and management.
Le Rhun E, Taillibert S, Chamberlain MC. Le Rhun E, et al. Expert Rev Neurother. 2015 Jun;15(6):601-20. doi: 10.1586/14737175.2015.1042455. Epub 2015 May 2. Expert Rev Neurother. 2015. PMID: 25936680 Review.
-
Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W. Wiestler B, et al. Acta Neuropathol. 2013 Sep;126(3):443-51. doi: 10.1007/s00401-013-1156-z. Epub 2013 Aug 1. Acta Neuropathol. 2013. PMID: 23904111
-
Anaplastic gliomas in adults: an update.
Izquierdo C, Joubert B, Ducray F. Izquierdo C, et al. Curr Opin Oncol. 2017 Nov;29(6):434-442. doi: 10.1097/CCO.0000000000000409. Curr Opin Oncol. 2017. PMID: 28901965 Review.
-
Wiestler B, Capper D, Hovestadt V, Sill M, Jones DT, Hartmann C, Felsberg J, Platten M, Feiden W, Keyvani K, Pfister SM, Wiestler OD, Meyermann R, Reifenberger G, Pietsch T, von Deimling A, Weller M, Wick W. Wiestler B, et al. Neuro Oncol. 2014 Dec;16(12):1630-8. doi: 10.1093/neuonc/nou138. Epub 2014 Jul 15. Neuro Oncol. 2014. PMID: 25028501 Free PMC article.
-
Wiestler B, Capper D, Sill M, Jones DT, Hovestadt V, Sturm D, Koelsche C, Bertoni A, Schweizer L, Korshunov A, Weiß EK, Schliesser MG, Radbruch A, Herold-Mende C, Roth P, Unterberg A, Hartmann C, Pietsch T, Reifenberger G, Lichter P, Radlwimmer B, Platten M, Pfister SM, von Deimling A, Weller M, Wick W. Wiestler B, et al. Acta Neuropathol. 2014 Oct;128(4):561-71. doi: 10.1007/s00401-014-1315-x. Epub 2014 Jul 10. Acta Neuropathol. 2014. PMID: 25008768
Cited by
-
Patel P, Baradaran H, Delgado D, Askin G, Christos P, John Tsiouris A, Gupta A. Patel P, et al. Neuro Oncol. 2017 Jan;19(1):118-127. doi: 10.1093/neuonc/now148. Epub 2016 Aug 8. Neuro Oncol. 2017. PMID: 27502247 Free PMC article. Review.
-
Research progress on radiotherapy technology and dose fraction scheme for advanced gliomas.
Zhang Y, Wang J. Zhang Y, et al. Transl Cancer Res. 2020 Dec;9(12):7642-7651. doi: 10.21037/tcr-20-1891. Transl Cancer Res. 2020. PMID: 35117363 Free PMC article. Review.
-
Lucena-Cacace A, Otero-Albiol D, Jiménez-García MP, Peinado-Serrano J, Carnero A. Lucena-Cacace A, et al. Oncotarget. 2017 Aug 28;8(59):99514-99530. doi: 10.18632/oncotarget.20577. eCollection 2017 Nov 21. Oncotarget. 2017. PMID: 29245920 Free PMC article.
-
Chamberlain MC, Colman H, Kim BT, Raizer J. Chamberlain MC, et al. J Neurooncol. 2017 Feb;131(3):507-516. doi: 10.1007/s11060-016-2241-7. Epub 2017 Feb 16. J Neurooncol. 2017. PMID: 28204914 Clinical Trial.
-
Current Management of Adult Diffuse Infiltrative Low Grade Gliomas.
Le Rhun E, Taillibert S, Chamberlain MC. Le Rhun E, et al. Curr Neurol Neurosci Rep. 2016 Feb;16(2):15. doi: 10.1007/s11910-015-0615-4. Curr Neurol Neurosci Rep. 2016. PMID: 26750130
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous